Literature DB >> 12562032

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

Natasha Press1, Mark W Tyndall, Evan Wood, Robert S Hogg, Julio S G Montaner.   

Abstract

A growing body of evidence suggests that a high degree of adherence is required to achieve and maintain a successful virologic response both in the short and long term. This holds true despite the definition of adherence or how it is measured. Reported differences in the degree of adherence required are likely due to differences in study design, difficulty measuring patient adherence, patient population studied, and the antiretroviral regimen studied. Virologic suppression and immunologic response often go hand in hand, but the impact of adherence on change in CD4 count tends to be delayed and, therefore, less apparent than the impact on HIV viral load. Degree of adherence has also been shown to be associated with AIDS-related morbidity, mortality, and hospitalizations.

Entities:  

Mesh:

Year:  2002        PMID: 12562032     DOI: 10.1097/00126334-200212153-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  33 in total

1.  Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication.

Authors:  Virender Kumar; William Encinosa
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

2.  The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care.

Authors:  Edward M Gardner; Moises E Maravi; Cornelis Rietmeijer; Arthur J Davidson; William J Burman
Journal:  Appl Health Econ Health Policy       Date:  2008       Impact factor: 2.561

Review 3.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.

Authors:  L Degenhardt; W Hall; M Warner-Smith
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

4.  Association between use of specific drugs and antiretroviral adherence: findings from MACH 14.

Authors:  M I Rosen; A C Black; J H Arnsten; K Goggin; R H Remien; J M Simoni; C E Golin; D R Bangsberg; H Liu
Journal:  AIDS Behav       Date:  2013-01

5.  Improved antiretroviral refill adherence in HIV-focused community pharmacies.

Authors:  Jennifer M Cocohoba; Patricia Murphy; Glen Pietrandoni; B Joseph Guglielmo
Journal:  J Am Pharm Assoc (2003)       Date:  2012 Sep-Oct

6.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  Predictors of adherence to antiretroviral therapy in rural Zambia.

Authors:  James G Carlucci; Aniset Kamanga; Robb Sheneberger; Bryan E Shepherd; Cathy A Jenkins; John Spurrier; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

Review 8.  The benefits of exercise training for quality of life in HIV/AIDS in the post-HAART era.

Authors:  Joseph T Ciccolo; Esbelle M Jowers; John B Bartholomew
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults.

Authors:  Monique M Duwell; Amy R Knowlton; Jean B Nachega; Anne Efron; Rene Goliath; Chelsea Morroni; Gary Maartens; Richard E Chaisson
Journal:  AIDS Patient Care STDS       Date:  2013-02       Impact factor: 5.078

10.  Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.

Authors:  Benjamin H Chi; Ronald A Cantrell; Isaac Zulu; Lloyd B Mulenga; Jens W Levy; Bushimbwa C Tambatamba; Stewart Reid; Albert Mwango; Alwyn Mwinga; Marc Bulterys; Michael S Saag; Jeffrey S A Stringer
Journal:  Int J Epidemiol       Date:  2009-02-17       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.